FILE - This April 30, 2020, file photo shows Gilead Sciences headquarters in Foster City, Calif. The European Medicines Agency says it has started a safety review after some patients taking the coronavirus drug remdesivir reported serious kidney problems. In a statement on Friday, Oct. 2, 2020, the EU regulator said it isn’t clear whether remdesivir is causing the “acute kidney injury,” but that the issue “warrants further investigation.” Remdesivir is one of the few licensed treatments for the coronavirus, in additional to the generic steroid dexamethasone. In July, health experts criticized the U.S. for buying up a significant portion of the drug, made by Gilead Sciences. (AP Photo/Ben Margot, File)
Featured Photo Galleries
